This study reports 20-year breast cancer incidence among participants in Women’s Health Initiative (WHI) trials randomized to conjugated equine estrogen (CEE) alone or with medroxyprogesterone acetate vs placebo.
This cohort study uses data from the Women’s Health Initiative study to compare the prognostic features and mortality rate of women with interval breast cancers diagnosed within 1 year or between 1 and 2.5 years of a mammogram with negative results with the prognostic features and mortality rate of women with breast cancers detected by screening.
This cohort study uses data from women enrolled in the Women’s Health Initiative (WHI) to examine the associations of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women in the United States.
This secondary analysis of the Women’s Health Initiative randomized clinical trial and observational study cohort investigates the association between body fat and breast cancer risk in postmenopausal women with normal body mass index.
Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women’s Health Initiative. JAMA Ophthalmol. 2018;136(1):3-10
This secondary analysis of the Women’s Health Initiative randomized clinical trial investigates the association of a low-fat dietary pattern vs a usual diet comparison with overall survival among women with breast cancer.
This cohort study examines the association between cataract surgery and total and cause-specific mortality in older patients with cataract in the Women’s Health Initiative.
This observational follow-up (cumulative 18 years) of postmenopausal women enrolled in 2 RCTs compared rates of all-cause, cardiovascular, and cancer mortality between groups receiving hormone therapy (conjugated equine estrogens [CEE] plus medroxyprogesterone acetate) or CEE alone vs placebo.
This cohort study compares the risk of cardiovascular disease in breast cancer survivors who received tamoxifen, aromatase inhibitors, both, or neither during a long-term follow-up period.
This study examined the influences of hormone therapy on breast cancer incidence during early and late postintervention phases in the Women’s Health Initiative trials, finding greater adverse influence for estrogen + progestin use and somewhat greater benefit for use of estrogen alone.
Manson and coauthors provide an update and overview of health outcomes during the intervention and poststopping phases of the Women’s Health Initiative (WHI) hormone therapy trials. In an accompanying Editorial, Nabel discusses how the WHI is a victory for women and their health.
You currently have no searches saved.